Zepbound Lawsuit: Side Effects, MDL Status, and Case Values

The Zepbound lawsuit is a mass personal injury case against Eli Lilly, brought by thousands of patients who say the company failed to warn them that its tirzepatide-based weight-loss drug could cause serious harms including stomach paralysis, intestinal blockages, pancreatitis, and vision loss. The cases are consolidated in a federal multidistrict litigation in Pennsylvania. As of mid-2026, no cases have been tried and no settlements have been reached.

What Plaintiffs Say Zepbound Did to Them

The core legal theory is failure to warn. Plaintiffs argue that Eli Lilly knew tirzepatide could cause severe problems but did not put adequate warnings on the label or in its marketing materials at the time they were prescribed the drug. A master complaint filed in November 2024 focuses on gastroparesis and gastroenteritis as the central injuries.1Motley Rice. Zepbound Lawsuits

The injuries alleged include:

  • Gastroparesis, often called stomach paralysis, in which the stomach cannot empty food normally.
  • Intestinal blockages and ileus, where the intestines stop contracting.
  • Nonarteritic anterior ischemic optic neuropathy (NAION), a form of vision loss caused by disrupted blood flow to the optic nerve that can be permanent.
  • Blood clots, including deep vein thrombosis and pulmonary embolism.
  • Pancreatitis, including necrotizing pancreatitis.
  • Surgical complications from retained food in the stomach leading to aspiration under anesthesia.

Tirzepatide works in part by slowing how fast the stomach empties, which helps people feel full longer. That same mechanism sits at the center of the safety claims: if the stomach empties too slowly, food can be retained, obstructions can form, and in serious cases the digestive tract can stop working. A 2025 case report in Cureus documented a 57-year-old man who developed acute functional gastric outlet obstruction on a low dose of tirzepatide, with symptoms resolving after he stopped the drug. Broader research on GLP-1 drugs has reported a roughly 3.5-fold increased risk of intestinal obstruction in patients with type 2 diabetes and a fourfold increase in retained gastric contents in patients undergoing endoscopy.2PMC/Cureus. Acute Functional Gastric Outlet Obstruction Associated With Low-Dose Tirzepatide

Zepbound’s label has always noted common gastrointestinal side effects like nausea and vomiting. Plaintiffs argue it understated the risk of far more serious conditions like stomach paralysis and intestinal obstruction.3Motley Rice. Tirzepatide Lawsuits4Sokolove Law. Mounjaro and Zepbound Lawsuits

Where the Cases Are Consolidated

The federal cases are gathered under MDL No. 3094, In re: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation, in the U.S. District Court for the Eastern District of Pennsylvania before Judge Karen Spencer Marston.5U.S. District Court, Eastern District of Pennsylvania. MDL 3094 – In Re Glucagon-like Peptide-1 Receptor Agonists Products Liability Litigation The MDL covers claims against Eli Lilly for Zepbound and Mounjaro and against Novo Nordisk for Ozempic, Wegovy, and related drugs, with each manufacturer facing its own set of allegations.

The docket has grown quickly. It held about 1,090 cases in October 2024, more than 3,000 by January 2026, and 3,763 by June 2026.6Robert King Law Firm. Zepbound Lawsuit Related state-court filings push some estimates higher.7Wagstaff Cartmell. GLP-1 Multidistrict Litigation MDL 3094: What Injured Patients Need to Know in 2026

Label Changes the FDA Has Required

Since Zepbound came to market, the FDA has ordered several updates to its label. Plaintiffs point to these changes as evidence the original warnings were inadequate:

The current Mounjaro label states the drug is “not recommended in patients with severe gastroparesis.”10FDA. Mounjaro Prescribing Information Plaintiffs argue that language should have appeared far earlier and still understates the true risk.

Where the Litigation Stands

The case is in discovery and pretrial motions. No bellwether trials have been scheduled, and no verdicts or settlements have been reached.6Robert King Law Firm. Zepbound Lawsuit

Several rulings have shaped the case. In August 2025, Judge Marston largely denied a motion to dismiss filed by Eli Lilly and Novo Nordisk. The core failure-to-warn and breach-of-warranty claims survived, though some allegations required amendment.11Seeger Weiss. Ozempic GLP-1 Lawsuit The court also ruled that plaintiffs bringing gastroparesis claims must support their diagnosis with a gastric emptying study.6Robert King Law Firm. Zepbound Lawsuit

In January 2026, the court issued Case Management Order No. 30, setting deadlines for expert disclosures and for briefing challenges to expert testimony. Those steps must be resolved before bellwether cases are selected.7Wagstaff Cartmell. GLP-1 Multidistrict Litigation MDL 3094: What Injured Patients Need to Know in 2026 Then in June 2026, Eli Lilly filed fresh motions to dismiss and to exclude plaintiffs’ experts, invoking federal preemption. The company’s position is that because the FDA approved the label, state-law failure-to-warn claims are blocked.6Robert King Law Firm. Zepbound Lawsuit

Vision Loss Claims Are in a Separate MDL

If your concern is vision loss rather than a gastrointestinal injury, the case is not in MDL 3094. In December 2025, the Judicial Panel on Multidistrict Litigation created MDL No. 3163, In re Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) Products Liability Litigation, also before Judge Marston in the Eastern District of Pennsylvania.12U.S. District Court, Eastern District of Pennsylvania. MDL 3163 – In Re GLP-1 RAs NAION Products Liability Litigation

The proceeding is small and new. One estimate placed it at roughly 30 to 40 cases as of early 2026.13Stark and Stark. Ozempic, Wegovy and Similar Drugs: What the Lawsuits Are About It relies in part on a 2024 JAMA Ophthalmology study by researchers at Harvard and Mass General Brigham that found diabetic patients taking semaglutide had a fourfold increased risk of NAION, and that overweight non-diabetic patients had more than a sevenfold increase. Lawsuits argue the risk extends across the GLP-1 class, including tirzepatide. A Science Day was set for June 2, 2026, to educate the court on the medical evidence.14Seeger Weiss. GLP-1 NAION Vision Loss Lawsuit

Who Can File a Claim

To pursue a Zepbound lawsuit in the current MDL, you generally need to have taken the branded, FDA-approved version of the drug as prescribed and then developed a serious medical condition that was not adequately described on the label at the time of your prescription. The MDL does not cover claims from people who used compounded, non-FDA-approved versions of tirzepatide.1Motley Rice. Zepbound Lawsuits

For a gastroparesis claim, the court requires a gastric emptying study to support the diagnosis.6Robert King Law Firm. Zepbound Lawsuit Blood clot injuries, meaning deep vein thrombosis and pulmonary embolism, are excluded from MDL 3094, though people with those injuries may still be able to file in other courts.1Motley Rice. Zepbound Lawsuits Filing deadlines depend on each state’s statute of limitations, which typically runs one to three years from the date the injury was discovered or should have been discovered.

What a Case Might Be Worth

Because nothing has settled and no trials have finished, any dollar figure at this stage is a projection. Some legal analysts have estimated that claims involving severe gastrointestinal complications could reach between $400,000 and $700,000 per case, with higher amounts for the most serious injuries such as stomach paralysis, surgical complications, and vision loss.15Reich and Binstock. Zepbound Lawsuit Others put the range at $100,000 to $500,000 or more depending on severity.16Uptown Injury. Zepbound Stomach Issues Actual outcomes will depend heavily on how the bellwether trials play out and on how the court rules on Eli Lilly’s preemption defense.